References for Ketamine and Esketamine

1. Berman, R.M., et al., Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000. 47(4): p. 351-4.

2. Abdallah, C.G., L.A. Averill, and J.H. Krystal, Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci, 2015. 1344: p. 66-77.

3. Murrough, J.W., et al., Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry, 2013. 74(4): p. 250-6.

4. Thase, M.E., New medications for treatment-resistant depression: a brief review of recent developments. CNS Spectr, 2017. 22(S1): p. 39-48.

5. Andrade, C., Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? J Clin Psychiatry, 2017. 78(7): p. e852-e857.

6. Loo, C., Can we confidently use ketamine as a clinical treatment for depression? Lancet Psychiatry, 2018. 5(1): p. 11-12.

7. Wilkinson, S.T., et al., The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry, 2018. 175(2): p. 150-158.

8. DiazGranados, N., et al., Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry, 2010. 71(12): p. 1605-11.

9. Price, R.B., et al., Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry, 2009. 66(5): p. 522-6.

10. Grunebaum, M.F., et al., Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry, 2018. 175(4): p. 327-335.

11. Serafini, G., et al., The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol, 2014. 12(5): p. 444-61.

12. Kaur, U., et al., Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatry Clin Neurosci, 2021. 271(3): p. 417-429.

13. Canuso, C.M., et al., Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry, 2018: p. appiajp201817060720.

14. Daly, E.J., et al., Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry, 2018. 75(2): p. 139-148.

15. Canuso, C.M., et al., Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry, 2018. 175(7): p. 620-630.

16. Popova, V., et al., Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry, 2019. 176(6): p. 428-438.

17. Wajs, E., et al., Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry, 2020. 81(3).

18. Salvadore, G. and J.B. Singh, Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther, 2013. 19(6): p. 428-36.

19. Krystal, J.H., G. Sanacora, and R.S. Duman, Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry, 2013. 73(12): p. 1133-41.

20. Rong, C., et al., Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Int J Environ Res Public Health, 2018. 15(4).

21. O'Brien, B., et al., Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord, 2021. 286: p. 320-329.